First-in-human, phase I study assessing imalumab (Bax69), a first-in-class anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody in advanced solid tumors
Mahalingam, Devalingam, Patel, Manish R., Sachdev, Jasgit C., Hart, Lowell L., Halama, Neils, Ramanathan, Ramesh K., Sarantopoulos, John, Liu, Xiaochun, Yazji, Salim, Jaeger, Dirk, Adib, Deyaa Rafaat, Kerschbaumer, Randolf, Tsimberidou, Apostolia Maria
Published in Journal of clinical oncology (20.05.2015)
Published in Journal of clinical oncology (20.05.2015)
Get full text
Journal Article